-
1
-
-
53249123632
-
-
4th edition. Lyon, France: IARC Press
-
Swerdlow SH, Campo E, Harris NL et al. (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon, France: IARC Press 2008; 233-237.
-
(2008)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
, pp. 233-237
-
-
Swerdlow, S.H.1
Campo, E.2
Harris, N.L.3
-
2
-
-
28844449677
-
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling
-
Fu K, Weisenburger DD, Greiner TC et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106: 4315-4321.
-
(2005)
Blood
, vol.106
, pp. 4315-4321
-
-
Fu, K.1
Weisenburger, D.D.2
Greiner, T.C.3
-
3
-
-
84881237232
-
European Mantle Cell Lymphoma Network. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network
-
Cheah CY, George A, Giné E et al. European Mantle Cell Lymphoma Network. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol 2013; 24: 2119-2123.
-
(2013)
Ann Oncol
, vol.24
, pp. 2119-2123
-
-
Cheah, C.Y.1
George, A.2
Giné, E.3
-
4
-
-
38349104577
-
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
-
Hoster E, Dreyling M, Klapper W et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
-
(2008)
Blood
, vol.111
, pp. 558-565
-
-
Hoster, E.1
Dreyling, M.2
Klapper, W.3
-
5
-
-
77950398416
-
Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network
-
Klapper W, Hoster E, Determann O et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009; 2: 103-111.
-
(2009)
J Hematop
, vol.2
, pp. 103-111
-
-
Klapper, W.1
Hoster, E.2
Determann, O.3
-
6
-
-
76749118059
-
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma
-
Fernàndez V, Salamero O, Espinet B et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010; 70: 1408-1418.
-
(2010)
Cancer Res
, vol.70
, pp. 1408-1418
-
-
Fernàndez, V.1
Salamero, O.2
Espinet, B.3
-
7
-
-
84860830052
-
Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
-
Nygren L, Baumgartner Wennerholm S, Klimkowska M et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 2012; 119: 4215-4223.
-
(2012)
Blood
, vol.119
, pp. 4215-4223
-
-
Nygren, L.1
Baumgartner Wennerholm, S.2
Klimkowska, M.3
-
8
-
-
84946232805
-
Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches
-
Dreyling M; European Mantle Cell Lymphoma Network. Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches. Am Soc Clin Oncol Educ Book 2014; 34: 191-198.
-
(2014)
Am Soc Clin Oncol Educ Book
, vol.34
, pp. 191-198
-
-
Dreyling, M.1
-
9
-
-
84862194194
-
Outcome of deferred initial therapy in mantle-cell lymphoma
-
Martin P, Chadburn A, Christos P et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27: 1209-1213.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1209-1213
-
-
Martin, P.1
Chadburn, A.2
Christos, P.3
-
11
-
-
84911467224
-
Follicular lymphoma, immunocytoma, and mantle cell lymphoma: randomized evaluation of curative radiotherapy in limited stage nodal disease
-
Engelhard M, Unterhalt M, Hansmann M et al. Follicular lymphoma, immunocytoma, and mantle cell lymphoma: randomized evaluation of curative radiotherapy in limited stage nodal disease. Ann Oncol 2008; 19 (suppl. 4): 418.
-
(2008)
Ann Oncol
, vol.19
, pp. 418
-
-
Engelhard, M.1
Unterhalt, M.2
Hansmann, M.3
-
12
-
-
34249704600
-
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis
-
Schulz H, Bohlius JF, Trelle S et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706-714.
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 706-714
-
-
Schulz, H.1
Bohlius, J.F.2
Trelle, S.3
-
13
-
-
20144376591
-
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
-
Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-1992.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1984-1992
-
-
Lenz, G.1
Dreyling, M.2
Hoster, E.3
-
14
-
-
61449265721
-
Immunochemotherapy (R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone-50 months update of the OSHO phase III study (OSHO#39)
-
abstr 12
-
Herold M, Haas A, Doerken B et al. Immunochemotherapy (R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone-50 months update of the OSHO phase III study (OSHO#39). Ann Oncol 2008; 19: abstr 12.
-
(2008)
Ann Oncol
, vol.19
-
-
Herold, M.1
Haas, A.2
Doerken, B.3
-
15
-
-
77956046528
-
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group
-
Gressin R, Caulet-Maugendre S, Deconinck E et al. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica 2010; 95: 1350-1357.
-
(2010)
Haematologica
, vol.95
, pp. 1350-1357
-
-
Gressin, R.1
Caulet-Maugendre, S.2
Deconinck, E.3
-
16
-
-
79951718283
-
Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen
-
Sachanas S, Pangalis GA, Vassilakopoulos TP et al. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leuk Lymphoma 2011; 52: 387-393.
-
(2011)
Leuk Lymphoma
, vol.52
, pp. 387-393
-
-
Sachanas, S.1
Pangalis, G.A.2
Vassilakopoulos, T.P.3
-
17
-
-
84864715966
-
Treatment of older patients with mantle-cell lymphoma
-
Kluin-Nelemans HC, Hoster E, Hermine O et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-531.
-
(2012)
N Engl J Med
, vol.367
, pp. 520-531
-
-
Kluin-Nelemans, H.C.1
Hoster, E.2
Hermine, O.3
-
18
-
-
84875840492
-
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantlecell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
-
Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantlecell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210.
-
(2013)
Lancet
, vol.381
, pp. 1203-1210
-
-
Rummel, M.J.1
Niederle, N.2
Maschmeyer, G.3
-
19
-
-
84900423736
-
Randomized trial of bendamustinerituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
-
Flinn IW, van der Jagt R, Kahl BS et al. Randomized trial of bendamustinerituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123: 2944-2952.
-
(2014)
Blood
, vol.123
, pp. 2944-2952
-
-
Flinn, I.W.1
van der Jagt, R.2
Kahl, B.S.3
-
20
-
-
20044381673
-
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
-
Ghielmini M, Schmitz SF, Cogliatti S et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705-711.
-
(2005)
J Clin Oncol
, vol.23
, pp. 705-711
-
-
Ghielmini, M.1
Schmitz, S.F.2
Cogliatti, S.3
-
21
-
-
84884755581
-
Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B
-
Huang YH, Hsiao LT, Hong YC et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765- 2772.
-
(2013)
J Clin Oncol
, vol.31
, pp. 2765- 2772
-
-
Huang, Y.H.1
Hsiao, L.T.2
Hong, Y.C.3
-
22
-
-
84865765565
-
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499
-
Smith MR, Li H, Gordon L et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012; 30: 3119-3126.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3119-3126
-
-
Smith, M.R.1
Li, H.2
Gordon, L.3
-
23
-
-
20144388941
-
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
-
Dreyling M, Lenz G, Hoster E et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677-2684.
-
(2005)
Blood
, vol.105
, pp. 2677-2684
-
-
Dreyling, M.1
Lenz, G.2
Hoster, E.3
-
24
-
-
77953045695
-
Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma
-
Hoster E, Metzner B, Forstpointner R et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2009; 114: 880.
-
(2009)
Blood (ASH Annual Meeting Abstracts)
, vol.114
, pp. 880
-
-
Hoster, E.1
Metzner, B.2
Forstpointner, R.3
-
25
-
-
84883133544
-
Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma
-
Final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)
-
Hermine O, Hoster E, Walewski J et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood (ASH Annual Meeting Abstracts) 2012; 120: 151.
-
(2012)
Blood (ASH Annual Meeting Abstracts)
, vol.120
, pp. 151
-
-
Hermine, O.1
Hoster, E.2
Walewski, J.3
-
26
-
-
74949115388
-
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909
-
Damon LE, Johnson JL, Niedzwiecki D et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27: 6101-6108.
-
(2009)
J Clin Oncol
, vol.27
, pp. 6101-6108
-
-
Damon, L.E.1
Johnson, J.L.2
Niedzwiecki, D.3
-
27
-
-
58549085393
-
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients
-
van 't Veer MB, de Jong D, MacKenzie M et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009; 144: 524-530.
-
(2009)
Br J Haematol
, vol.144
, pp. 524-530
-
-
Van't Veer, M.B.1
De Jong, D.2
MacKenzie, M.3
-
28
-
-
84863822702
-
Nordic Lymphoma Group. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
-
Geisler CH, Kolstad A, Laurell A et al. Nordic Lymphoma Group. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355-362.
-
(2012)
Br J Haematol
, vol.158
, pp. 355-362
-
-
Geisler, C.H.1
Kolstad, A.2
Laurell, A.3
-
29
-
-
84872054301
-
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
-
Delarue R, Haioun C, Ribrag V et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 2013; 121: 48-53.
-
(2013)
Blood
, vol.121
, pp. 48-53
-
-
Delarue, R.1
Haioun, C.2
Ribrag, V.3
-
30
-
-
84895061381
-
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC
-
Touzeau C, Leux C, Bouabdallah R et al. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Ann Hematol 2014; 93: 233-242.
-
(2014)
Ann Hematol
, vol.93
, pp. 233-242
-
-
Touzeau, C.1
Leux, C.2
Bouabdallah, R.3
-
31
-
-
27244452464
-
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
-
Romaguera JE, Fayad L, Rodriguez MA et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013-7023.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7013-7023
-
-
Romaguera, J.E.1
Fayad, L.2
Rodriguez, M.A.3
-
32
-
-
84855796484
-
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
-
Merli F, Luminari S, Ilariucci F et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156: 346-353.
-
(2012)
Br J Haematol
, vol.156
, pp. 346-353
-
-
Merli, F.1
Luminari, S.2
Ilariucci, F.3
-
33
-
-
84878457954
-
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
-
Bernstein SH, Epner E, Unger JM et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 2013; 24: 1587-1593.
-
(2013)
Ann Oncol
, vol.24
, pp. 1587-1593
-
-
Bernstein, S.H.1
Epner, E.2
Unger, J.M.3
-
34
-
-
84899755490
-
High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
-
Laurell A, Kolstad A, Jerkeman M et al. High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial. Leuk Lymphoma 2014; 55: 1206-1208.
-
(2014)
Leuk Lymphoma
, vol.55
, pp. 1206-1208
-
-
Laurell, A.1
Kolstad, A.2
Jerkeman, M.3
-
35
-
-
84911497441
-
Role of high-dose cytarabine and total body irradiation conditioning before autologous stem cell transplantation in mantle cell lymphoma-a comparison of Nordic MCL2, HOVON 45, and European MCL Younger Trials
-
Hoster E, Geisler GH, Doorduijn JK et al. Role of high-dose cytarabine and total body irradiation conditioning before autologous stem cell transplantation in mantle cell lymphoma-a comparison of Nordic MCL2, HOVON 45, and European MCL Younger Trials. Blood (ASH Annual Meeting Abstracts) 2013; 122: 3367.
-
(2013)
Blood (ASH Annual Meeting Abstracts)
, vol.122
, pp. 3367
-
-
Hoster, E.1
Geisler, G.H.2
Doorduijn, J.K.3
-
36
-
-
84883220460
-
Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa trial, a Lysa study
-
Le Gouill S, Callanan M, Macintyre E et al. Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa trial, a Lysa study. Blood (ASH Annual Meeting Abstracts) 2012; 120: 152.
-
(2012)
Blood (ASH Annual Meeting Abstracts)
, vol.120
, pp. 152
-
-
Le Gouill, S.1
Callanan, M.2
Macintyre, E.3
-
37
-
-
84905575740
-
Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO)
-
Krüger WH, Hirt C, Basara N et al. Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol 2014; 93: 1587-1597.
-
(2014)
Ann Hematol
, vol.93
, pp. 1587-1597
-
-
Krüger, W.H.1
Hirt, C.2
Basara, N.3
-
38
-
-
84875606235
-
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation
-
Visco C, Finotto S, Zambello R et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31: 1442-1449.
-
(2013)
J Clin Oncol
, vol.31
, pp. 1442-1449
-
-
Visco, C.1
Finotto, S.2
Zambello, R.3
-
39
-
-
68949102180
-
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
-
Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3822-3829
-
-
Hess, G.1
Herbrecht, R.2
Romaguera, J.3
-
40
-
-
61649094981
-
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
-
Goy A, Bernstein SH, Kahl BS et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009; 20: 520-525.
-
(2009)
Ann Oncol
, vol.20
, pp. 520-525
-
-
Goy, A.1
Bernstein, S.H.2
Kahl, B.S.3
-
41
-
-
84887030194
-
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
-
Zinzani PL, Vose JM, Czuczman MS et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013; 24: 2892-2897.
-
(2013)
Ann Oncol
, vol.24
, pp. 2892-2897
-
-
Zinzani, P.L.1
Vose, J.M.2
Czuczman, M.S.3
-
42
-
-
84881225049
-
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
-
Wang ML, Rule S, Martin P et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507-516.
-
(2013)
N Engl J Med
, vol.369
, pp. 507-516
-
-
Wang, M.L.1
Rule, S.2
Martin, P.3
-
43
-
-
79959923820
-
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapyrefractory mantle cell lymphoma
-
Lamm W, Kaufmann H, Raderer M et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapyrefractory mantle cell lymphoma. Haematologica 2011; 96: 1008-1014.
-
(2011)
Haematologica
, vol.96
, pp. 1008-1014
-
-
Lamm, W.1
Kaufmann, H.2
Raderer, M.3
-
44
-
-
79951700533
-
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
-
Kouroukis CT, Fernandez LA, Crump M et al. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma 2011; 52: 394-399.
-
(2011)
Leuk Lymphoma
, vol.52
, pp. 394-399
-
-
Kouroukis, C.T.1
Fernandez, L.A.2
Crump, M.3
-
45
-
-
23944481410
-
Phase II trial of single-agent temsirolimus (CCI- 779) for relapsed mantle cell lymphoma
-
Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI- 779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-5356.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5347-5356
-
-
Witzig, T.E.1
Geyer, S.M.2
Ghobrial, I.3
-
46
-
-
49049087320
-
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group
-
Ansell SM, Inwards DJ, Rowland KM, Jr et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113: 508-514.
-
(2008)
Cancer
, vol.113
, pp. 508-514
-
-
Ansell, S.M.1
Inwards, D.J.2
Rowland Jr, K.M.3
-
47
-
-
79953182631
-
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
-
Ansell SM, Tang H, Kurtin PJ et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011; 12: 361-368.
-
(2011)
Lancet Oncol
, vol.12
, pp. 361-368
-
-
Ansell, S.M.1
Tang, H.2
Kurtin, P.J.3
-
48
-
-
84863971730
-
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
-
Renner C, Zinzani PL, Gressin R et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97: 1085-1091.
-
(2012)
Haematologica
, vol.97
, pp. 1085-1091
-
-
Renner, C.1
Zinzani, P.L.2
Gressin, R.3
-
49
-
-
84889099537
-
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study
-
Goy A, Sinha R, Williams ME et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31: 3688-3695.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3688-3695
-
-
Goy, A.1
Sinha, R.2
Williams, M.E.3
-
50
-
-
84863107308
-
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
-
Wang M, Fayad L, Wagner-Bartak N et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716-723.
-
(2012)
Lancet Oncol
, vol.13
, pp. 716-723
-
-
Wang, M.1
Fayad, L.2
Wagner-Bartak, N.3
-
51
-
-
84857740069
-
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
-
Zaja F, De Luca S, Vitolo U et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97: 416-422.
-
(2012)
Haematologica
, vol.97
, pp. 416-422
-
-
Zaja, F.1
De Luca, S.2
Vitolo, U.3
-
52
-
-
79960490364
-
Treatment of younger patients with mantle cell lymphoma
-
Harel S, Delarue R, Ribrag V et al. Treatment of younger patients with mantle cell lymphoma. Semin Hematol 2011; 48: 194-207.
-
(2011)
Semin Hematol
, vol.48
, pp. 194-207
-
-
Harel, S.1
Delarue, R.2
Ribrag, V.3
-
53
-
-
77952839682
-
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma
-
Ruan J, Martin P, Coleman M et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 2010; 116: 2655-2664.
-
(2010)
Cancer
, vol.116
, pp. 2655-2664
-
-
Ruan, J.1
Martin, P.2
Coleman, M.3
-
54
-
-
70449727887
-
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma
-
Wang M, Oki Y, Pro B et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 5213-5218.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5213-5218
-
-
Wang, M.1
Oki, Y.2
Pro, B.3
-
55
-
-
84911487354
-
Radioimmunotherapy in relapsed/ refractory mantle cell lymphoma patients: final results of a European MCL Network phase II trial
-
Ferrero S, Pastore A, Forstpointner R et al. Radioimmunotherapy in relapsed/ refractory mantle cell lymphoma patients: final results of a European MCL Network phase II trial. Blood (ASH Annual Meeting Abstracts) 2013; 122: 4384.
-
(2013)
Blood (ASH Annual Meeting Abstracts)
, vol.122
, pp. 4384
-
-
Ferrero, S.1
Pastore, A.2
Forstpointner, R.3
-
56
-
-
84891442057
-
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study
-
Morschhauser FA, Cartron G, Thieblemont C et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912-2919.
-
(2013)
J Clin Oncol
, vol.31
, pp. 2912-2919
-
-
Morschhauser, F.A.1
Cartron, G.2
Thieblemont, C.3
-
57
-
-
84901724050
-
A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
-
Kahl BS, Spurgeon SE, Furman RR et al. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014; 123: 3398-3405.
-
(2014)
Blood
, vol.123
, pp. 3398-3405
-
-
Kahl, B.S.1
Spurgeon, S.E.2
Furman, R.R.3
-
58
-
-
84902254046
-
The single-agent Bcl-2 inhibitor ABT- 199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients
-
Davids MS, Seymour JF, Gerecitano JF et al. The single-agent Bcl-2 inhibitor ABT- 199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. Blood (ASH Annual Meeting Abstracts) 2013; 122: 1789.
-
(2013)
Blood (ASH Annual Meeting Abstracts)
, vol.122
, pp. 1789
-
-
Davids, M.S.1
Seymour, J.F.2
Gerecitano, J.F.3
-
59
-
-
33845515497
-
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (RFCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
-
Forstpointner R, Unterhalt M, Dreyling M et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (RFCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003-4008.
-
(2006)
Blood
, vol.108
, pp. 4003-4008
-
-
Forstpointner, R.1
Unterhalt, M.2
Dreyling, M.3
-
60
-
-
84882746664
-
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation
-
Cassaday RD, Guthrie KA, Budde EL et al. Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013; 19: 1403-1406.
-
(2013)
Biol Blood Marrow Transplant
, vol.19
, pp. 1403-1406
-
-
Cassaday, R.D.1
Guthrie, K.A.2
Budde, E.L.3
-
61
-
-
85027906668
-
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma
-
Jul 18 [Epub ahead of print]
-
Robinson S, Dreger P, Caballero D et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia 2014; Jul 18 [Epub ahead of print].
-
(2014)
Leukemia
-
-
Robinson, S.1
Dreger, P.2
Caballero, D.3
-
62
-
-
84903462466
-
Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma-the Lugano Classification
-
in press
-
Cheson B, Fisher R, Barrington S et al. Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma-the Lugano Classification. JCO 2014; in press.
-
(2014)
JCO
-
-
Cheson, B.1
Fisher, R.2
Barrington, S.3
-
63
-
-
77951453410
-
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study
-
Pott C, Hoster E, Delfau-Larue MH et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010; 115: 3215-3223.
-
(2010)
Blood
, vol.115
, pp. 3215-3223
-
-
Pott, C.1
Hoster, E.2
Delfau-Larue, M.H.3
-
64
-
-
33845249942
-
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma
-
Ladetto M, Magni M, Pagliano G et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006; 12: 1270-1276.
-
(2006)
Biol Blood Marrow Transplant
, vol.12
, pp. 1270-1276
-
-
Ladetto, M.1
Magni, M.2
Pagliano, G.3
-
65
-
-
0035879607
-
Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
-
Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.
-
(2001)
Clin Infect Dis
, vol.33
, pp. 139-144
-
-
Dykewicz, C.A.1
|